{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:51:00Z","timestamp":1791384660199,"version":"4.3.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000901","name":"Juvenile Diabetes Research Foundation International","doi-asserted-by":"publisher","award":["3-SRA-2022-1186-S-B"],"award-info":[{"award-number":["3-SRA-2022-1186-S-B"]}],"id":[{"id":"10.13039\/100000901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims\/hypothesis<\/jats:title>\n                    <jats:p>\n                      Monitoring of beta cell function in individuals with islet autoimmunity who do not require insulin treatment (preclinical type 1 diabetes) is normally done via OGTTs, posing major challenges given the invasiveness of the test. Here, we validated a disposition index (DI) derived from continuous glucose monitoring (CGM) metrics (DI\n                      <jats:sup>CGM<\/jats:sup>\n                      ), which is a proxy of beta cell function, against the gold-standard OGTT DI (DI\n                      <jats:sup>MM<\/jats:sup>\n                      ), in a cohort of individuals with one or more islet autoantibodies who do not require insulin treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Participants underwent a 3\u00a0h 10-point OGTT with measurement of glucose, insulin and C-peptide while wearing a blinded CGM. The sensor was started 24\u00a0h prior to the OGTT. DI\n                      <jats:sup>CGM<\/jats:sup>\n                      was computed using CGM data during the 3\u00a0h OGTT and two blood glucose calibrations, and compared with the DI from the oral minimal model (DI\n                      <jats:sup>MM<\/jats:sup>\n                      ), which uses plasma glucose, insulin and C-peptide. The association between the baseline DI\n                      <jats:sup>CGM<\/jats:sup>\n                      and duration of glucose levels above 7.8 mmol\/l (140 mg\/dl) (TA140) at 1\u00a0year was explored.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-four participants (median age 16.8 years [IQR 13.5\u201327.7] ) were enrolled, of whom 18 completed both the OGTT (ten with pre-stage\u00a01, seven with stage\u00a01 and one with stage\u00a03a type 1 diabetes) and CGM at baseline, and had repeat CGM 1\u00a0year later. The baseline DI\n                      <jats:sup>CGM<\/jats:sup>\n                      was highly correlated with the DI\n                      <jats:sup>MM<\/jats:sup>\n                      (\n                      <jats:italic>r<\/jats:italic>\n                      =0.90,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001). Lower baseline DI\n                      <jats:sup>CGM<\/jats:sup>\n                      was associated with higher 1\u00a0year TA140 (\n                      <jats:italic>r<\/jats:italic>\n                      =\u22120.61,\n                      <jats:italic>p<\/jats:italic>\n                      =0.014) and higher 1\u00a0year mean sensor glucose (\n                      <jats:italic>r<\/jats:italic>\n                      =\u22120.62,\n                      <jats:italic>p<\/jats:italic>\n                      =0.020).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\/interpretation<\/jats:title>\n                    <jats:p>\n                      Beta cell function can be estimated using CGM during a glucose load. DI\n                      <jats:sup>CGM<\/jats:sup>\n                      correlates with a 1\u00a0year clinically relevant outcome (TA140) in individuals with islet autoimmunity who do not require insulin therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00125-026-06895-z","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:56:06Z","timestamp":1791381366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CGM-derived disposition index estimates beta cell function in individuals with islet autoimmunity who do not require insulin treatment; changes in the disposition index precede changes identified by CGM metrics 1\u00a0year later"],"prefix":"10.1007","author":[{"given":"Hadija","family":"Marchiori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Schiavon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Tichy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Alguard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"DeSousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Del Favero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L.","family":"Gaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Sherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Dalla Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Galderisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"6","key":"6895_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41577-023-00985-4","volume":"24","author":"KC Herold","year":"2024","unstructured":"Herold KC, Delong T, Perdigoto AL, Biru N, Brusko TM, Walker LSK (2024) The immunology of type 1 diabetes. Nat Rev Immunol 24(6):435\u2013451. https:\/\/doi.org\/10.1038\/s41577-023-00985-4","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"6895_CR2","doi-asserted-by":"publisher","first-page":"a041623","DOI":"10.1101\/cshperspect.a041623","volume":"15","author":"KC Herold","year":"2025","unstructured":"Herold KC, Krischer JP (2025) The pathogenesis of type 1 diabetes. Cold Spring Harb Perspect Med 15(11):a041623. https:\/\/doi.org\/10.1101\/cshperspect.a041623","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"11","key":"6895_CR3","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.2337\/db24-0163","volume":"73","author":"M Martino","year":"2024","unstructured":"Martino M, Galderisi A, Evans-Molina C, Dayan C (2024) Revisiting the pattern of loss of \u03b2-cell function in preclinical type 1 diabetes. Diabetes 73(11):1769\u20131779. https:\/\/doi.org\/10.2337\/db24-0163","journal-title":"Diabetes"},{"issue":"12","key":"6895_CR4","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1007\/s00125-023-06011-5","volume":"66","author":"A Galderisi","year":"2023","unstructured":"Galderisi A, Carr ALJ, Martino M, Taylor P, Senior P, Dayan C (2023) Quantifying beta cell function in the preclinical stages of type 1 diabetes. Diabetologia 66(12):2189\u20132199. https:\/\/doi.org\/10.1007\/s00125-023-06011-5","journal-title":"Diabetologia"},{"issue":"6","key":"6895_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1159\/000543035","volume":"97","author":"MJ Haller","year":"2024","unstructured":"Haller MJ, Bell KJ, Besser REJ et al (2024) ISPAD Clinical Practice Consensus Guidelines 2024: screening, staging, and strategies to preserve beta-cell function in children and adolescents with type 1 diabetes. Horm Res Paediatr 97(6):529\u2013545. https:\/\/doi.org\/10.1159\/000543035","journal-title":"Horm Res Paediatr"},{"issue":"7","key":"6895_CR6","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.2337\/dc24-2908","volume":"48","author":"LM Jacobsen","year":"2025","unstructured":"Jacobsen LM, Felton JL, Nathan BM, Speake C, Krischer J, Herold KC (2025) Type 1 diabetes TrialNet: leading the charge in disease prediction, prevention, and immunotherapeutic mechanistic understanding. Diabetes Care 48(7):1112\u20131124. https:\/\/doi.org\/10.2337\/dc24-2908","journal-title":"Diabetes Care"},{"issue":"2","key":"6895_CR7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/pedi.13149","volume":"22","author":"KA Driscoll","year":"2021","unstructured":"Driscoll KA, Tamura R, Johnson SB et al (2021) Adherence to oral glucose tolerance testing in children in stage 1 of type 1 diabetes: the TEDDY study. Pediatr Diabetes 22(2):360\u2013368. https:\/\/doi.org\/10.1111\/pedi.13149","journal-title":"Pediatr Diabetes"},{"issue":"3","key":"6895_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.2337\/dc22-1297","volume":"46","author":"DM Wilson","year":"2023","unstructured":"Wilson DM, Pietropaolo SL, Acevedo-Calado M et al (2023) CGM metrics identify dysglycemic states in participants from the TrialNet Pathway to Prevention Study. Diabetes Care 46(3):526\u2013534. https:\/\/doi.org\/10.2337\/dc22-1297","journal-title":"Diabetes Care"},{"issue":"1","key":"6895_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1210\/clinem\/dgad472","volume":"109","author":"A Ylescupidez","year":"2023","unstructured":"Ylescupidez A, Speake C, Pietropaolo SL et al (2023) OGTT metrics surpass continuous glucose monitoring data for T1D prediction in multiple-autoantibody-positive individuals. J Clin Endocrinol Metab 109(1):57\u201367. https:\/\/doi.org\/10.1210\/clinem\/dgad472","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6895_CR10","doi-asserted-by":"publisher","first-page":"7214","DOI":"10.1038\/s41467-023-42581-z","volume":"14","author":"A Ylescupidez","year":"2023","unstructured":"Ylescupidez A, Bahnson HT, O\u2019Rourke C, Lord S, Speake C, Greenbaum CJ (2023) A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes. Nat Commun 14(1):7214. https:\/\/doi.org\/10.1038\/s41467-023-42581-z","journal-title":"Nat Commun"},{"issue":"7","key":"6895_CR11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrendo.2017.3","volume":"13","author":"BP Kovatchev","year":"2017","unstructured":"Kovatchev BP (2017) Metrics for glycaemic control \u2013 from HbA1c to continuous glucose monitoring. Nat Rev Endocrinol 13(7):425\u2013436. https:\/\/doi.org\/10.1038\/nrendo.2017.3","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"6895_CR12","doi-asserted-by":"publisher","first-page":"E354","DOI":"10.1152\/ajpendo.00407.2024","volume":"329","author":"M Schiavon","year":"2025","unstructured":"Schiavon M, Vella A, Dalla Man C (2025) Quantitative estimation of disposition index from postprandial glucose data across the spectrum of glucose tolerance. Am J Physiol Endocrinol Metab 329(2):E354\u2013E366. https:\/\/doi.org\/10.1152\/ajpendo.00407.2024","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"Suppl 1","key":"6895_CR13","doi-asserted-by":"publisher","first-page":"S212","DOI":"10.2337\/diabetes.51.2007.s212","volume":"51","author":"RN Bergman","year":"2002","unstructured":"Bergman RN, Ader M, Huecking K, Van Citters G (2002) Accurate assessment of \u03b2-cell function: the hyperbolic correction. Diabetes 51(Suppl 1):S212\u2013S220. https:\/\/doi.org\/10.2337\/diabetes.51.2007.s212","journal-title":"Diabetes"},{"issue":"1 Suppl 1","key":"6895_CR14","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 2. Diagnosis and classification of diabetes: standards of care in diabetes \u2013 2025. Diabetes Care 48(1 Suppl 1):S27\u2013S49. https:\/\/doi.org\/10.2337\/dc25-S002","journal-title":"Diabetes Care"},{"issue":"1","key":"6895_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2337\/diabetes.50.1.150","volume":"50","author":"E Breda","year":"2001","unstructured":"Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C (2001) Oral glucose tolerance test minimal model indexes of \u03b2-cell function and insulin sensitivity. Diabetes 50(1):150\u2013158. https:\/\/doi.org\/10.2337\/diabetes.50.1.150","journal-title":"Diabetes"},{"issue":"5","key":"6895_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1109\/10.995680","volume":"49","author":"C Dalla Man","year":"2002","unstructured":"Dalla Man C, Caumo A, Cobelli C (2002) The oral glucose minimal model: estimation of insulin sensitivity from a meal test. IEEE Trans Biomed Eng 49(5):419\u2013429. https:\/\/doi.org\/10.1109\/10.995680","journal-title":"IEEE Trans Biomed Eng"},{"issue":"4","key":"6895_CR17","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2337\/db13-1198","volume":"63","author":"C Cobelli","year":"2014","unstructured":"Cobelli C, Dalla Man C, Toffolo G, Basu R, Vella A, Rizza R (2014) The oral minimal model method. Diabetes 63(4):1203\u20131213. https:\/\/doi.org\/10.2337\/db13-1198","journal-title":"Diabetes"},{"issue":"12 Pt 1","key":"6895_CR18","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1109\/TBME.2006.883792","volume":"53","author":"C Dalla Man","year":"2006","unstructured":"Dalla Man C, Camilleri M, Cobelli C (2006) A system model of oral glucose absorption: validation on gold standard data. IEEE Trans Biomed Eng 53(12 Pt 1):2472\u20132478. https:\/\/doi.org\/10.1109\/TBME.2006.883792","journal-title":"IEEE Trans Biomed Eng"},{"issue":"11","key":"6895_CR19","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.2337\/diabetes.54.11.3265","volume":"54","author":"C Dalla Man","year":"2005","unstructured":"Dalla Man C, Campioni M, Polonsky K et al (2005) Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal model assessment of \u03b2-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes 54(11):3265\u20133273. https:\/\/doi.org\/10.2337\/diabetes.54.11.3265","journal-title":"Diabetes"},{"issue":"4","key":"6895_CR20","doi-asserted-by":"publisher","first-page":"E637","DOI":"10.1152\/ajpendo.00319.2003","volume":"287","author":"C Dalla Man","year":"2004","unstructured":"Dalla Man C, Caumo A, Basu R, Rizza R, Toffolo G, Cobelli C (2004) Minimal model estimation of glucose absorption and insulin sensitivity from oral test: validation with a tracer method. Am J Physiol Endocrinol Metab 287(4):E637\u2013E643. https:\/\/doi.org\/10.1152\/ajpendo.00319.2003","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"6895_CR21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2337\/diab.41.3.368","volume":"41","author":"E Van Cauter","year":"1992","unstructured":"Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates from C-peptide levels Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41(3):368\u2013377. https:\/\/doi.org\/10.2337\/diab.41.3.368","journal-title":"Diabetes"},{"issue":"5","key":"6895_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1089\/dia.2014.0230","volume":"17","author":"S Del Favero","year":"2015","unstructured":"Del Favero S, Facchinetti A, Sparacino G, Cobelli C, AP@home Consortium (2015) Retrofitting of continuous glucose monitoring traces allows more accurate assessment of glucose control in outpatient studies. Diabetes Technol Ther 17(5):355\u2013363. https:\/\/doi.org\/10.1089\/dia.2014.0230","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"6895_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","volume":"11","author":"T Battelino","year":"2023","unstructured":"Battelino T, Alexander CM, Amiel SA et al (2023) Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol 11(1):42\u201357. https:\/\/doi.org\/10.1016\/S2213-8587(22)00319-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"6895_CR24","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s00125-020-05365-4","volume":"64","author":"M Redondo","year":"2021","unstructured":"Redondo M, Nathan B, Jacobsen L et al (2021) Index60 as an additional diagnostic criterion for type 1 diabetes. Diabetologia 64(4):836\u2013844. https:\/\/doi.org\/10.1007\/s00125-020-05365-4","journal-title":"Diabetologia"},{"issue":"2","key":"6895_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2337\/dc21-0944","volume":"45","author":"MN Brandon","year":"2021","unstructured":"Brandon MN, Maria JR, Heba I et al (2021) Index60 identifies individuals at appreciable risk for stage 3 among an autoantibody-positive population with normal 2-hour glucose levels: implications for current staging criteria of type 1 diabetes. Diabetes Care 45(2):311\u2013318. https:\/\/doi.org\/10.2337\/dc21-0944","journal-title":"Diabetes Care"},{"issue":"4","key":"6895_CR26","doi-asserted-by":"publisher","first-page":"610","DOI":"10.2337\/dbi20-0054","volume":"71","author":"EK Sims","year":"2022","unstructured":"Sims EK, Besser REJ, Dayan C et al (2022) Screening for type 1 diabetes in the general population: a status report and perspective. Diabetes 71(4):610\u2013623. https:\/\/doi.org\/10.2337\/dbi20-0054","journal-title":"Diabetes"},{"issue":"3","key":"6895_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S2213-8587(25)00363-8","volume":"14","author":"LM Quinn","year":"2026","unstructured":"Quinn LM, Elliott J, Papanikolaou T et al (2026) Feasibility of general population screening for type 1 diabetes in the UK: the ELSA study. Lancet Diabetes Endocrinol 14(3):197\u2013199. https:\/\/doi.org\/10.1016\/S2213-8587(25)00363-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"6895_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jcjd.2025.11.001","volume":"50","author":"PA Senior","year":"2026","unstructured":"Senior PA, Marwaha A, Witteman HO et al (2026) General population screening for type 1 diabetes in Canada \u2013 CanScreenT1D. Can J Diabetes 50(1):58\u201361. https:\/\/doi.org\/10.1016\/j.jcjd.2025.11.001","journal-title":"Can J Diabetes"},{"issue":"10","key":"6895_CR29","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1111\/dom.15779","volume":"26","author":"V Cherubini","year":"2024","unstructured":"Cherubini V, Mozzillo E, Iafusco D et al (2024) Follow-up and monitoring programme in children identified in early-stage type 1 diabetes during screening in the general population of Italy. Diabetes Obes Metab 26(10):4197\u20134202. https:\/\/doi.org\/10.1111\/dom.15779","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"6895_CR30","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.2337\/db24-1000","volume":"74","author":"HM Ismail","year":"2025","unstructured":"Ismail HM, Cuthbertson D, Galderisi A et al (2025) The disposition index in autoantibody-positive individuals at risk for type 1 diabetes. Diabetes 74(7):1196\u20131204. https:\/\/doi.org\/10.2337\/db24-1000","journal-title":"Diabetes"},{"issue":"11","key":"6895_CR31","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1210\/clinem\/dgaf086","volume":"110","author":"A Galderisi","year":"2025","unstructured":"Galderisi A, Bonet J, Ismail HM et al (2025) Metabolic phenotype of stage 1 and stage 2 type 1 diabetes using modelling of \u03b2 cell function. J Clin Endocrinol Metab 110(11):3168\u20133178. https:\/\/doi.org\/10.1210\/clinem\/dgaf086","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"6895_CR32","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1210\/clinem\/dgab344","volume":"106","author":"A Galderisi","year":"2021","unstructured":"Galderisi A, Moran A, Evans-Molina C et al (2021) Early impairment of insulin sensitivity, \u03b2-cell responsiveness, and insulin clearance in youth with Stage 1 type 1 diabetes. J Clin Endocrinol Metab 106(9):2660\u20132669. https:\/\/doi.org\/10.1210\/clinem\/dgab344","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"6895_CR33","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1210\/clinem\/dgae048","volume":"109","author":"EK Sims","year":"2024","unstructured":"Sims EK, Cuthbertson D, Jacobsen L et al (2024) Comparisons of metabolic measures to predict T1D vs detect a preventive treatment effect in high-risk individuals. J Clin Endocrinol Metab 109(8):2116\u20132123. https:\/\/doi.org\/10.1210\/clinem\/dgae048","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6895_CR34","doi-asserted-by":"publisher","first-page":"522.e1","DOI":"10.1016\/j.ajog.2014.11.010","volume":"212","author":"DA Racusin","year":"2015","unstructured":"Racusin DA, Antony K, Showalter L, Sharma S, Haymond M, Aagaard KM (2015) Candy twists as an alternative to the glucola beverage in gestational diabetes mellitus screening. Am J Obstet Gynecol 212(4):522.e1-e5. https:\/\/doi.org\/10.1016\/j.ajog.2014.11.010","journal-title":"Am J Obstet Gynecol"},{"issue":"5 Pt 1","key":"6895_CR35","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/s0002-9378(99)70099-2","volume":"181","author":"ME Lamar","year":"1999","unstructured":"Lamar ME, Kuehl TJ, Cooney AT, Gayle LJ, Holleman S, Allen SR (1999) Jelly beans as an alternative to a fifty-gram glucose beverage for gestational diabetes screening. Am J Obstet Gynecol 181(5 Pt 1):1154\u20131157. https:\/\/doi.org\/10.1016\/s0002-9378(99)70099-2","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"6895_CR36","doi-asserted-by":"publisher","first-page":"e100007","DOI":"10.7759\/cureus.100007","volume":"17","author":"A El Alam","year":"2025","unstructured":"El Alam A, Fleifel M, Awdi AAL et al (2025) Oral glucose tolerance test for everyone: affordable, accessible, and well-tolerated alternatives to traditional glucose liquid. Cureus 17(12):e100007. https:\/\/doi.org\/10.7759\/cureus.100007","journal-title":"Cureus"},{"issue":"2","key":"6895_CR37","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2337\/db25-0801","volume":"75","author":"A Galderisi","year":"2025","unstructured":"Galderisi A, Carr ALJ, Taylor P et al (2025) Baseline insulin secretion determines response to abatacept in stage 1 type 1 diabetes. Diabetes 75(2):229\u2013240. https:\/\/doi.org\/10.2337\/db25-0801","journal-title":"Diabetes"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06895-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06895-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06895-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:56:07Z","timestamp":1791381367000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-026-06895-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":37,"alternative-id":["6895"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06895-z","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We acknowledge the analytical support of the Research Service of the Yale Mineral Metabolism Laboratory for some of the biochemical measurements. We are grateful to A.M. Santoro and C. Todeasa (Yale University, New Haven, CT, USA) for the completion of insulin and C-peptide assays. The study was presented at the ADA Meeting in New Orleans, 5\u20138 June 2026.","order":1,"name":"Ethics","label":"Acknowledgements","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Data are available upon request to the corresponding authors for research purposes or other academic use. Anonymised CGM profile will be made available along with deidentified participants\u2019 characteristics for 5 years from the publication of this manuscript.","order":2,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"MATLAB codes are available from the corresponding author upon request for research purposes or other academic use.","order":3,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Padova within the CRUI-CARE Agreement. AG and JLS were supported by BreakthroughT1D (3-SRA-2022-1186-S-B).\u00a0HM and CDM received funding from the European Union\u2019s Horizon Europe research and innovation programme under grant agreement No 101099093. MS, CDM and SDF were supported under the initiative National Recovery and Resilience Plan (NRRP), Mission 4, Component 2, Investment 1.1, ERC sector PE7 \u2018Systems and Communication Engineering\u2019 call for tender no. 1409 published on 14 September 2022 by the Italian Ministry of University and Research (MUR) and funded by the European Union NextGenerationEU project PRIN 2022 PNRR-P2022XSFA7.","order":4,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Dexcom (CA, USA) provided CGM sensors at a research cost. The company had no role in the study design, data analysis or interpretation.","order":5,"name":"Ethics","label":"Authors\u2019 relationships and activities","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"AG and JLS designed and conducted the study, drafted the manuscript and revised it. HM and CDM developed the CGM-based metric to compute the DI, drafted the manuscript and revised it. MS developed the CGM-based metric to compute the DI, and revised the manuscript. SDF contributed to the data analysis and to the revision of the manuscript. JG contributed to the clinical study and critically revised the analysis and the final version of the manuscript. MDS, MA and ET researched data, contributed to the clinical study and reviewed the manuscript. All authors approved the final version of the manuscript. AG is the guarantor of the study, and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.","order":6,"name":"Ethics","label":"Contribution statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}